ID

31454

Descripción

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease; ODM derived from: https://clinicaltrials.gov/show/NCT00880620

Link

https://clinicaltrials.gov/show/NCT00880620

Palabras clave

Versiones (1)
  1. 23/8/18 23/8/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

23 de agosto de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Parkinson's Disease NCT00880620

Inglés

Eligibility Parkinson's Disease NCT00880620

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. able to understand and willing to voluntarily sign an informed consent form (icf) and health insurance portability and accountability act (hipaa) authorization or local equivalent if applicable.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
2. diagnosed with idiopathic pd.
Descripción

Parkinson Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0030567
3. ld-naïve: defined as subjects not exposed to ld or catechol-o-methyl transferase inhibitors for more than 30 days and the exposure is not within 4 weeks prior to study enrollment.
Descripción

Levodopa naive | Absence Exposure to Levodopa | Absence Exposure to Catechol-O-methyltransferase inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0023570
UMLS CUI [1,2]
C0919936
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0332157
UMLS CUI [2,3]
C0023570
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C0332157
UMLS CUI [3,3]
C0595267
4. if currently taking anticholinergic therapy, amantadine, or a monoamine oxidase type b (mao-b) inhibitor, maintains a stable regimen for at least 4 weeks prior to baseline, and agrees to maintain the stable regimen throughout study participation.
Descripción

Anticholinergic Agents Therapy Stable | Amantadine | MAO-B Inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0242896
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0205360
UMLS CUI [2]
C0002403
UMLS CUI [3]
C2917433
5. agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.
Descripción

Contraceptive methods Agreement

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0700589
UMLS CUI [1,2]
C0680240
6. able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.
Descripción

Protocol Compliance | Patient Available Clinic Visits | Patient Available Telephone call

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0525058
UMLS CUI [2,1]
C0030705
UMLS CUI [2,2]
C0470187
UMLS CUI [2,3]
C0008952
UMLS CUI [3,1]
C0030705
UMLS CUI [3,2]
C0470187
UMLS CUI [3,3]
C0302186
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. pregnant or breastfeeding.
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
2. diagnosed with atypical parkinsonism or any known secondary parkinsonian syndrome.
Descripción

Atypical Parkinsonism | Secondary Parkinson Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4302185
UMLS CUI [2]
C0030569
3. prior functional neurosurgical treatment for pd or if such procedures are anticipated during study participation.
Descripción

Neurosurgical Procedures Functional Parkinson Disease | Neurosurgical Procedures Anticipated

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0524850
UMLS CUI [1,2]
C0205245
UMLS CUI [1,3]
C0030567
UMLS CUI [2,1]
C0524850
UMLS CUI [2,2]
C3840775
4. use of nonselective mao inhibitors.
Descripción

Monoamine oxidase inhibitors, non-selective

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3653330
5. use of dopamine agonists within 30 days prior to screening.
Descripción

Dopamine Agonists

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0178601
6. unable to tolerate a placebo regimen, in the investigator's opinion.
Descripción

Placebo study Receive Unable

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0683952
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C1299582
7. treatment of psychosis with any antipsychotic.
Descripción

Treatment Psychotic Disorders | Antipsychotic Agents

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0033975
UMLS CUI [2]
C0040615
8. history of seizure or epilepsy.
Descripción

Epilepsy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0014544
9. active or prior medical condition or prior surgical procedure that would interfere with ld absorption.
Descripción

Medical condition Interferes with Levodopa Absorption | Operative Surgical Procedure Interferes with Levodopa Absorption

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0023570
UMLS CUI [1,4]
C0237442
UMLS CUI [2,1]
C0543467
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0023570
UMLS CUI [2,4]
C0237442
10. history of narrow-angle glaucoma.
Descripción

Angle Closure Glaucoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0017605
11. subjects with a history of malignant melanoma.
Descripción

Melanoma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0025202
12. history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome.
Descripción

Myocardial Infarction | Atrial arrhythmia Residual | Nodal rhythm disorder Residual | Ventricular arrhythmia Residual | Upper gastrointestinal hemorrhage | Neuroleptic Malignant Syndrome

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2,1]
C0085611
UMLS CUI [2,2]
C1609982
UMLS CUI [3,1]
C0264893
UMLS CUI [3,2]
C1609982
UMLS CUI [4,1]
C0085612
UMLS CUI [4,2]
C1609982
UMLS CUI [5]
C0041909
UMLS CUI [6]
C0027849
13. received any investigational medications during the 30 days prior to screening.
Descripción

Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
Volver a la parte superior de la página

Similar models

Eligibility Parkinson's Disease NCT00880620

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
1. able to understand and willing to voluntarily sign an informed consent form (icf) and health insurance portability and accountability act (hipaa) authorization or local equivalent if applicable.
boolean
C0021430 (UMLS CUI [1])
Parkinson Disease
Item
2. diagnosed with idiopathic pd.
boolean
C0030567 (UMLS CUI [1])
Levodopa naive | Absence Exposure to Levodopa | Absence Exposure to Catechol-O-methyltransferase inhibitor
Item
3. ld-naïve: defined as subjects not exposed to ld or catechol-o-methyl transferase inhibitors for more than 30 days and the exposure is not within 4 weeks prior to study enrollment.
boolean
C0023570 (UMLS CUI [1,1])
C0919936 (UMLS CUI [1,2])
C0332197 (UMLS CUI [2,1])
C0332157 (UMLS CUI [2,2])
C0023570 (UMLS CUI [2,3])
C0332197 (UMLS CUI [3,1])
C0332157 (UMLS CUI [3,2])
C0595267 (UMLS CUI [3,3])
Anticholinergic Agents Therapy Stable | Amantadine | MAO-B Inhibitor
Item
4. if currently taking anticholinergic therapy, amantadine, or a monoamine oxidase type b (mao-b) inhibitor, maintains a stable regimen for at least 4 weeks prior to baseline, and agrees to maintain the stable regimen throughout study participation.
boolean
C0242896 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0205360 (UMLS CUI [1,3])
C0002403 (UMLS CUI [2])
C2917433 (UMLS CUI [3])
Contraceptive methods Agreement
Item
5. agrees to use a medically acceptable method of contraception throughout the study and for 1 month after completing the study.
boolean
C0700589 (UMLS CUI [1,1])
C0680240 (UMLS CUI [1,2])
Protocol Compliance | Patient Available Clinic Visits | Patient Available Telephone call
Item
6. able and willing to comply with the protocol, including availability for all scheduled clinic visits and telephone calls.
boolean
C0525058 (UMLS CUI [1])
C0030705 (UMLS CUI [2,1])
C0470187 (UMLS CUI [2,2])
C0008952 (UMLS CUI [2,3])
C0030705 (UMLS CUI [3,1])
C0470187 (UMLS CUI [3,2])
C0302186 (UMLS CUI [3,3])
Item Group
C0680251 (UMLS CUI)
Pregnancy | Breast Feeding
Item
1. pregnant or breastfeeding.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Atypical Parkinsonism | Secondary Parkinson Disease
Item
2. diagnosed with atypical parkinsonism or any known secondary parkinsonian syndrome.
boolean
C4302185 (UMLS CUI [1])
C0030569 (UMLS CUI [2])
Neurosurgical Procedures Functional Parkinson Disease | Neurosurgical Procedures Anticipated
Item
3. prior functional neurosurgical treatment for pd or if such procedures are anticipated during study participation.
boolean
C0524850 (UMLS CUI [1,1])
C0205245 (UMLS CUI [1,2])
C0030567 (UMLS CUI [1,3])
C0524850 (UMLS CUI [2,1])
C3840775 (UMLS CUI [2,2])
Monoamine oxidase inhibitors, non-selective
Item
4. use of nonselective mao inhibitors.
boolean
C3653330 (UMLS CUI [1])
Dopamine Agonists
Item
5. use of dopamine agonists within 30 days prior to screening.
boolean
C0178601 (UMLS CUI [1])
Placebo study Receive Unable
Item
6. unable to tolerate a placebo regimen, in the investigator's opinion.
boolean
C0683952 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])
Treatment Psychotic Disorders | Antipsychotic Agents
Item
7. treatment of psychosis with any antipsychotic.
boolean
C0087111 (UMLS CUI [1,1])
C0033975 (UMLS CUI [1,2])
C0040615 (UMLS CUI [2])
Epilepsy
Item
8. history of seizure or epilepsy.
boolean
C0014544 (UMLS CUI [1])
Medical condition Interferes with Levodopa Absorption | Operative Surgical Procedure Interferes with Levodopa Absorption
Item
9. active or prior medical condition or prior surgical procedure that would interfere with ld absorption.
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0023570 (UMLS CUI [1,3])
C0237442 (UMLS CUI [1,4])
C0543467 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0023570 (UMLS CUI [2,3])
C0237442 (UMLS CUI [2,4])
Angle Closure Glaucoma
Item
10. history of narrow-angle glaucoma.
boolean
C0017605 (UMLS CUI [1])
Melanoma
Item
11. subjects with a history of malignant melanoma.
boolean
C0025202 (UMLS CUI [1])
Myocardial Infarction | Atrial arrhythmia Residual | Nodal rhythm disorder Residual | Ventricular arrhythmia Residual | Upper gastrointestinal hemorrhage | Neuroleptic Malignant Syndrome
Item
12. history of myocardial infarction with residual atrial, nodal, or ventricular arrhythmias, upper gastrointestinal hemorrhage, or neuroleptic malignant syndrome.
boolean
C0027051 (UMLS CUI [1])
C0085611 (UMLS CUI [2,1])
C1609982 (UMLS CUI [2,2])
C0264893 (UMLS CUI [3,1])
C1609982 (UMLS CUI [3,2])
C0085612 (UMLS CUI [4,1])
C1609982 (UMLS CUI [4,2])
C0041909 (UMLS CUI [5])
C0027849 (UMLS CUI [6])
Investigational New Drugs
Item
13. received any investigational medications during the 30 days prior to screening.
boolean
C0013230 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial